VIVS Runs Triple Digits Premarket as Eli Lilly Milestone Check Exceeds Its Entire Market Cap

VivoSim Labs went from a 52-week-low print Tuesday to a triple-digit premarket runner Wednesday morning, July 15, on a press release that hit at 8:05 AM ET. The tape tagged the mid-$3s in the early premarket on volume that turned the float over more than a dozen times, then faded back below $2 as of this writing at 8:49 AM ET. That fade is the first fact worth registering: the average premarket buyer paid more than the current price, and that overhead supply doesn’t disappear at the bell.

The catalyst

This one’s real. VivoSim announced it received a $5 million milestone payment from Eli Lilly, triggered by the dosing of the first patient in Phase 2 studies of the inflammatory bowel disease drug it previously developed and sold outright to Lilly. The backstory: the company sold its FXR program to Lilly in March 2025 for $10 million upfront plus potential milestone payments of up to $50 million tied to development, regulatory and commercial milestones. The drug’s development is entirely in Lilly’s hands, but VivoSim remains eligible for up to $45 million in additional milestones over time.

The company paired the check with guidance: it expects revenue growth of 500%+ in FY2027. Context matters here — FY2026 revenue was $131,000, so 500% growth still lands under a million dollars. The $5 million payment is the substance; it’s non-dilutive cash that exceeded the company’s entire market cap coming into the day.

What was visible beforehand

The setup was hiding in plain sight. The 10-K for fiscal 2026 hit EDGAR Tuesday, July 14 — after an NT 10-K late-filing notice on June 29 — and the year showed a loss of $13.8 million, or $5.35 per share. Stock closed Tuesday pennies off its 52-week low on light volume. Nobody was positioned for good news, and the float is thin enough that nobody needed to be.

The mechanics and the fade

Structure is the whole trade. A sub-3M float against tens of millions of premarket shares is a loaded spring in both directions, and LULD halts are a live risk at the open. The dilution machinery is documented: the company raised approximately $1.8 million via its ATM, issuing 701,729 shares, over a six-month stretch last year, and shares outstanding roughly doubled over the past year. Management has stated conditions raise substantial doubt about the company’s ability to continue as a going concern. With a fresh 10-K on file and a 90% gap, an ATM print into strength would surprise no one — though the $5 million check genuinely eases the near-term pressure that usually forces those sales.

The second act

Premarket VWAP sits up in the mid-$2s, well above the last print. That’s the pivot: reclaim it on regular-session volume and the premarket high in the mid-$3s is the obvious magnet, with the $5.30 52-week high beyond that. Fail it, and $1.50 is first support, then the mid-$0.80s prior-close zone — a full round trip is always on the table when a float this small fades before the open. Watch the first 15 minutes: expanding volume holding above $1.50 keeps the second act alive; drying volume below VWAP says the move already happened.

This is analysis, not investment advice — do your own homework and size accordingly.

The Setup: This is a Float Squeeze play — read the pattern guide to learn how these setups typically unfold.